Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04517149 · ClinicalTrials.gov registry record · Phase 1

4D-125 in Patients With X-Linked Retinitis Pigmentosa (XLRP)

A Phase 1 study of X-Linked Retinitis Pigmentosa, sponsored by 4D Molecular Therapeutics.

Active
Registry status
Phase 1
Development phase
21
Enrollment target
8
Study locations

NCT04517149 is a Phase 1 study of X-Linked Retinitis Pigmentosa that is active but no longer recruiting, run by 4D Molecular Therapeutics. The registered enrollment target is 21 participants, below the 56-participant average among 8 other X-Linked Retinitis Pigmentosa trials with a reported enrollment target (62% lower). The trial reports 8 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04517149, a Phase 1 study of X-Linked Retinitis Pigmentosa, is active but no longer recruiting, sponsored by 4D Molecular Therapeutics.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
21 participants
Enrollment target
8
Study locations

Study Summary

This is a Phase 1/2 multicenter study with two parallel parts: an observational natural history cohort and an open-label, prospective interventional trial in males with non-syndromic X-linked retinitis pigmentosa (XLRP) due to mutations in the gene encoding retinitis pigmentosa GTPase regulator (RPGR).

Conditions Studied

X-Linked Retinitis Pigmentosa

Interventions

  • OTHER Observational
  • BIOLOGICAL 4D-125 IVT Injection

Study Locations (8)

Colorado

  • University of Colorado - Aurora

Florida

  • Vitreo Retinal Associates - Gainesville

Michigan

  • University of Michigan Kellogg Eye Center - Ann Arbor

New York

  • Columbia University Medical Center/Edward Harkness Eye Institute - New York

North Carolina

  • Duke University Eye Center/Dept. of Ophthalmology - Durham

Oregon

  • Casey Eye Institute, Oregon Health and Science University - Portland

Texas

  • Retina Foundation of the Southwest - Dallas

Utah

  • University of Utah John A. Moran Eye Center - Salt Lake City

Trial Details

FieldValue
Enrollment Target 21 participants
Start Date 2020-06-09
Est. Completion 2029-05
Phase Phase 1

Sponsor

4D Molecular Therapeutics

9 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04517149

The ClinicalTrials.gov registry entry for NCT04517149 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 56-participant average among 8 other X-Linked Retinitis Pigmentosa trials with a reported enrollment target (62% lower). The listed sponsor is 4D Molecular Therapeutics, which has 9 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with X-Linked Retinitis Pigmentosa appearing as the primary indexed condition, and to 2 interventions - of which Observational is the first listed.

NCT04517149 reports 8 study locations spanning 8 distinct geographic areas - top geographies include Colorado, Florida, Michigan.

Frequently Asked Questions

What is clinical trial NCT04517149 about?

NCT04517149 is a clinical study titled "4D-125 in Patients With X-Linked Retinitis Pigmentosa (XLRP)". This is a Phase 1/2 multicenter study with two parallel parts: an observational natural history cohort and an open-label, prospective interventional trial in males with non-syndromic X-linked retinitis pigmentosa (XLRP) due to mutations in the gene encoding retinitis pigmentosa GTPase regulator (RPG...

What is the current status of trial NCT04517149?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2020-06-09. Estimated completion is 2029-05.

What conditions does trial NCT04517149 study?

This clinical trial studies the following conditions: X-Linked Retinitis Pigmentosa.

What interventions are being tested in trial NCT04517149?

The interventions under investigation include: Observational (OTHER), 4D-125 IVT Injection (BIOLOGICAL).

Who is sponsoring clinical trial NCT04517149?

This trial is sponsored by 4D Molecular Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04517149 being conducted?

This trial has 8 study locations across Colorado, Florida, Michigan, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for X-Linked Retinitis Pigmentosa

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

X-Linked Retinitis Pigmentosa

All registered trials for this condition

Colorado

All trials with a study site in Colorado

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.